News
November
Nov.16, 2023
Release
Stream-I, Inc. Launches New Home Palliative Care Support Service 'Home Care Base'
Nov.06, 2023
Notice
Transcript of the FY2023 2Q Financial Results Conference
Nov.02, 2023
Notice
2023 SHIONOGI Integrated Report have been issued
Nov.01, 2023
Notice
Presentation Materials for FY2023 2Q financial results
October
Oct.31, 2023
Notice
Notice Regarding Interim Dividend for the Fiscal Year Ending March 31, 2023
Oct.31, 2023
Notice
Financial Results and Supplement and Press Conference for FY2023 2Q
Oct.31, 2023
Release
Notice Regarding Results of an Early Retirement Program
Oct.24, 2023
Notice
Presentation Materilals and Transcript of Sustainability Meeting
Oct.23, 2023
Notice
Notice of alert regarding impersonation accounts
Oct.16, 2023
Notice
Transcript of HIV follow-up meeting
September
Sep.21, 2023
Notice
Transcript of the ESWI 2023 follow-up meeting
Sep.19, 2023
Notice
Presentation Material of ESWI 2023 Follow Up Meeting
August
Aug.30, 2023
Release
Shionogi Announces Corporate Reorganization and Personnel Reassignment
Aug.29, 2023
Release
Flomox® Fine Granules for children oral cephem antibiotic agent Launched in China
Aug.02, 2023
Notice
Transcript of the First Quarter of FY2023 Financial Results Conference
July
Jul.31, 2023
Notice
Financial Results and supplement for FY2023 1Q
Jul.31, 2023
Notice
Presentation Materials for FY2023 1Q financial results
Jul.10, 2023
Release
Notice Regarding Implementation of an Early Retirement Program
June
Jun.30, 2023
Release
Eddingpharm Announces Approval of Mulpleta® (Lusutrombopag) in China
Jun.21, 2023
Release
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
Jun.19, 2023
Release
Update on Antigen Design for Universal Sarbecovirus Vaccine by Shionogi and KOTAI
Jun.15, 2023
Release
Shionogi to Announces Appointment of Corporate Officers
Jun.05, 2023
Notice
Transcript of Medium-Term Business Plan STS2030 Revision
Jun.01, 2023
Notice
Presentation Materials for Revision of the Medium-Term Business Plan STS2030
Jun.01, 2023
Release
Revision of the Medium-Term Business Plan STS2030
May
May.24, 2023
Release
Orphan Drug Designation for Redasemtide for Dystrophic Epidermolysis Bullosa
May.15, 2023
Notice
Transcript of FY2022 Financial Results
May.10, 2023
Notice
Presentation Materials for FY2022 financial results
May.09, 2023
Notice
Financial Results and supplement for FY2022
April
Apr.27, 2023
Release
Shionogi to Announce Personnel Reassignment
Apr.24, 2023
Release
Notice of Revisions to Dividend Forecasts (Dividend Increase)
Apr.21, 2023
Release
Position and Policy Regarding Reduction of the Investment Unit
March
Apr.03, 2023
Notice
Transcript for HIV Business Meeting
Mar.30, 2023
Notice
Presentation material for HIV Business Meeting
Mar.29, 2023
Release
Notice of a Limited Partner Investment Agreement with LSP Dementia Fund
Mar.20, 2023
Release
SHIONOGI to Announce Executive Appointments
Mar.13, 2023
Release
Shionogi to Announce Personnel Reassignment
Mar.08, 2023
Release
Shionogi Wins Second Prize in NIKKEI Integrated Report Award 2022
February
Feb.27, 2023
Release
Shionogi to Announce Personnel Reassignment
Feb.24, 2023
Notice
Presentation Material and Transcript of CROI 2023 Follow Up Meeting
Feb.22, 2023
Release
Shionogi Supports Victims of the Earthquake in Turkey and Syria
Feb.15, 2023
Release
Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
Feb.13, 2023
Release
Notice Regarding Completion of Cancellation of Treasury Shares
Feb.01, 2023
Notice
Transcript of FY2022 Q3 Financial Results
January
Jan.30, 2023
Notice
Presentation Materials for FY2022 2Q financial results
Jan.30, 2023
Notice
Financial Results and supplement for FY2022 2Q
Jan.30, 2023
Release
Notice of Revisions to Earnings Forecasts for the fiscal year ending March 31, 2023
Jan.24, 2023
Release
Shionogi to Announce Personnel Reassignment